Exosome Component 9 Antibody (1090209) [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: IHC, ICC/IF
• Clone: 1090209
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 350

Exosome Component 9 Antibody (1090209) [Alexa Fluor® 350] Summary

• Immunogen: Synthetic Peptide
  Accession # Q06265
• Specificity: Detects a synthetic peptide specific for hEXOSC9 around amino acid 300 in Direct ELISA.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry
  • Immunohistochemistry

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Exosome Component 9 Antibody (1090209) [Alexa Fluor® 350]

• Autoantigen PM/Scl 1
• EC 3.1.13
• exosome complex component RRP45
• exosome complex exonuclease RRP45
• Exosome Component 9
• p5
• p6
• P75 polymyositis-scleroderma overlap syndrome associated autoantigen
• PCH1D
• PM/Scl-75
• PMSCL autoantigen, 75kD
• PMSCL1
• polymyositis/scleroderma autoantigen 1 (75kD)
• Polymyositis/scleroderma autoantigen 1
• polymyositis/scleroderma autoantigen 1, 75kDa
• RRP45
• Rrp45p

Background

Exosome Component 9 (EXOSC9) is a 49 kDa protein and one of the six core proteins of the RNA exosome complex. It is known that EXOSC9 is necessary for the normal differentiation of epidermal tissues. EXOSC9 is also necessary for P-body formation, stress resistance and tumorigenicity in cancers. Depletion of EXOSC9 attenuates stress resistance and P-body formation in cancer cells and higher EXOSC9 activity correlates with poor prognosis in some types of cancers.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.